This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBPO China Biologic Products (CBPO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About China Biologic Products Stock (NASDAQ:CBPO) Get CBPO alerts:Sign Up Key Stats Today's Range$117.27▼$120.0550-Day Range$117.88▼$119.9952-Week Range$99.74▼$120.05Volume390,921 shsAverage Volume148,695 shsMarket Capitalization$4.72 billionP/E Ratio33.52Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China. Read More Receive CBPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Biologic Products and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBPO Stock News HeadlinesHow is China changing?August 5, 2024 | bbc.co.ukChina hits back at Trump with tariffs on $60bn of US goodsDecember 14, 2023 | bbc.comB$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.September 16 at 2:00 AM | Weiss Ratings (Ad)Biologic Excipients industry research covers a wide range of industries with predicted CAGR 10% during 2023-2030June 22, 2023 | marketwatch.comNerve Biologic Products Market 2023-2030: Future Hypothesize and ascending UpdatesMay 6, 2023 | marketwatch.comBiologic Excipients Market by 2030: Future Scope and PredictionsApril 16, 2023 | marketwatch.comWhat is the US’ ‘One China’ policy, and why is it important?April 14, 2023 | nypost.comNNerve Biologic Products Market in 2023: Insights and Strategies | 2029April 9, 2023 | marketwatch.comSee More Headlines CBPO Stock Analysis - Frequently Asked Questions How were China Biologic Products' earnings last quarter? China Biologic Products Holdings, Inc. (NASDAQ:CBPO) announced its quarterly earnings results on Sunday, March, 28th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.22. The biopharmaceutical company had revenue of $112.10 million for the quarter. China Biologic Products had a net margin of 27.43% and a trailing twelve-month return on equity of 8.32%. What other stocks do shareholders of China Biologic Products own? Based on aggregate information from My MarketBeat watchlists, some other companies that China Biologic Products investors own include Meta Platforms (META), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings3/28/2021Today9/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBPO CIK1369868 Webwww.chinabiologic.com Phone861065983111FaxN/AEmployees2,269Year Founded2002Profitability EPS (Trailing Twelve Months)$4.28 Trailing P/E Ratio33.52 Forward P/E Ratio30.93 P/E GrowthN/ANet Income$138.81 million Net Margins27.43% Pretax MarginN/A Return on Equity8.32% Return on Assets7.64% Debt Debt-to-Equity RatioN/A Current Ratio12.01 Quick Ratio10.13 Sales & Book Value Annual Sales$503.70 million Price / Sales9.38 Cash Flow$5.01 per share Price / Cash Flow23.93 Book Value$45.09 per share Price / Book2.66Miscellaneous Outstanding Shares39,360,000Free FloatN/AMarket Cap$4.72 billion OptionableOptionable Beta0.47 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CBPO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Biologic Products Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Biologic Products With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
